Natera (NASDAQ:NTRA) CEO Sells $32,134,171.88 in Stock

Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 160,703 shares of the firm’s stock in a transaction dated Monday, November 3rd. The shares were sold at an average price of $199.96, for a total transaction of $32,134,171.88. Following the transaction, the chief executive officer directly owned 144,816 shares in the company, valued at approximately $28,957,407.36. The trade was a 52.60% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Steven Leonard Chapman also recently made the following trade(s):

• On Tuesday, October 28th, Steven Leonard Chapman sold 3,680 shares of Natera stock. The shares were sold at an average price of $191.46, for a total transaction of $704,572.80.
• On Monday, October 27th, Steven Leonard Chapman sold 2,335 shares of Natera stock. The shares were sold at an average price of $192.32, for a total transaction of $449,067.20.
• On Tuesday, October 21st, Steven Leonard Chapman sold 1,603 shares of Natera stock. The shares were sold at an average price of $187.95, for a total transaction of $301,283.85.
• On Wednesday, October 1st, Steven Leonard Chapman sold 14,083 shares of Natera stock. The stock was sold at an average price of $160.00, for a total transaction of $2,253,280.00.
• On Tuesday, September 30th, Steven Leonard Chapman sold 9,109 shares of Natera stock. The shares were sold at an average price of $162.05, for a total transaction of $1,476,113.45.
• On Tuesday, September 2nd, Steven Leonard Chapman sold 5,079 shares of Natera stock. The shares were sold at an average price of $166.53, for a total transaction of $845,805.87.

Natera Trading Down 0.4%

NTRA stock traded down $0.70 on Monday, hitting $198.23. 1,636,729 shares of the company’s stock traded hands, compared to its average volume of 1,129,900. Natera, Inc. has a 1-year low of $121.01 and a 1-year high of $200.76. The stock has a market cap of $27.21 billion, a price-to-earnings ratio of -103.79 and a beta of 1.74. The stock has a fifty day moving average of $175.16 and a 200-day moving average of $162.43.

Natera (NASDAQ:NTRA) last released its earnings results on Thursday, August 7th. The medical research company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.14). Natera had a negative net margin of 12.89% and a negative return on equity of 22.22%. The business had revenue of $546.60 million for the quarter, compared to analyst estimates of $476.84 million. During the same period in the prior year, the company earned ($0.30) earnings per share. The firm’s revenue for the quarter was up 32.2% on a year-over-year basis. Natera has set its FY 2025 guidance at EPS. On average, equities research analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Natera

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Bank of Jackson Hole Trust bought a new stake in Natera in the 1st quarter valued at $29,000. Hilltop National Bank bought a new stake in shares of Natera in the 2nd quarter worth about $33,000. Oliver Lagore Vanvalin Investment Group bought a new stake in shares of Natera in the 2nd quarter worth about $36,000. Sound Income Strategies LLC grew its holdings in shares of Natera by 95.7% in the 3rd quarter. Sound Income Strategies LLC now owns 225 shares of the medical research company’s stock worth $39,000 after purchasing an additional 110 shares during the last quarter. Finally, TCTC Holdings LLC grew its holdings in shares of Natera by 114.8% in the 1st quarter. TCTC Holdings LLC now owns 232 shares of the medical research company’s stock worth $33,000 after purchasing an additional 124 shares during the last quarter. Institutional investors own 99.90% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the stock. Zacks Research lowered shares of Natera from a “hold” rating to a “strong sell” rating in a research report on Monday, October 20th. BNP Paribas Exane raised shares of Natera from an “underperform” rating to a “neutral” rating and set a $172.00 price objective on the stock in a research report on Monday, October 27th. Royal Bank Of Canada set a $268.00 price objective on shares of Natera and gave the company an “outperform” rating in a research report on Tuesday, September 2nd. Cowen reaffirmed a “buy” rating on shares of Natera in a research report on Friday, August 8th. Finally, Stephens reaffirmed an “overweight” rating and set a $183.00 price objective on shares of Natera in a research report on Friday, August 15th. One analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, three have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $194.89.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.